The global market for Monoclonal Antibodies for Non-small Cell Lung Cancer was valued at US$ 11680 million in the year 2024 and is projected to reach a revised size of US$ 24560 million by 2031, growing at a CAGR of 11.2% during the forecast period.

Monoclonal Antibodies for Non-small Cell Lung Cancer Market

Non-Monoclonal Antibodies for Non-small Cell Lung Cancer are a class of biological agents targeting specific targets of non-small cell lung cancer (NSCLC), aiming to enhance the body's immune response by targeting specific antigens or immune checkpoints on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. These monoclonal antibodies can be used to treat advanced or recurrent NSCLC, often in combination with chemotherapy or other immunotherapies, to increase treatment efficacy and improve patient survival.

North American market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer include Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., Henlius Biopharma Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Innovent Biologics Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibodies for Non-small Cell Lung Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibodies for Non-small Cell Lung Cancer.

The Monoclonal Antibodies for Non-small Cell Lung Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal Antibodies for Non-small Cell Lung Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Monoclonal Antibodies for Non-small Cell Lung Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Monoclonal Antibodies for Non-small Cell Lung Cancer Market Report

Report Metric	Details
Report Name	Monoclonal Antibodies for Non-small Cell Lung Cancer Market
Accounted market size in year	US$ 11680 million
Forecasted market size in 2031	US$ 24560 million
CAGR	11.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	5 mg/mL 10 mg/mL 25 mg/mL 50 mg/mL
Segment by Application	Hospitals Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., Henlius Biopharma Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Innovent Biologics Co., Ltd, Junshi Biosciences Co., Ltd, BeiGene, Ltd, Akeso, Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Monoclonal Antibodies for Non-small Cell Lung Cancer Market growing?

Ans: The Monoclonal Antibodies for Non-small Cell Lung Cancer Market witnessing a CAGR of 11.2% during the forecast period 2025-2031.

What is the Monoclonal Antibodies for Non-small Cell Lung Cancer Market size in 2031?

Ans: The Monoclonal Antibodies for Non-small Cell Lung Cancer Market size in 2031 will be US$ 24560 million.

Who are the main players in the Monoclonal Antibodies for Non-small Cell Lung Cancer Market report?

Ans: The main players in the Monoclonal Antibodies for Non-small Cell Lung Cancer Market are Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., Henlius Biopharma Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Innovent Biologics Co., Ltd, Junshi Biosciences Co., Ltd, BeiGene, Ltd, Akeso, Inc

What are the Application segmentation covered in the Monoclonal Antibodies for Non-small Cell Lung Cancer Market report?

Ans: The Applications covered in the Monoclonal Antibodies for Non-small Cell Lung Cancer Market report are Hospitals, Clinic, Others

What are the Type segmentation covered in the Monoclonal Antibodies for Non-small Cell Lung Cancer Market report?

Ans: The Types covered in the Monoclonal Antibodies for Non-small Cell Lung Cancer Market report are 5 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL

1 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Overview

1.1 Product Definition

1.2 Monoclonal Antibodies for Non-small Cell Lung Cancer by Type

1.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2024 VS 2031)

1.2.2 5 mg/mL

1.2.3 10 mg/mL

1.2.4 25 mg/mL

1.2.5 50 mg/mL

1.3 Monoclonal Antibodies for Non-small Cell Lung Cancer by Application

1.3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2024 VS 2031)

1.3.2 Hospitals

1.3.3 Clinic

1.3.4 Others

1.4 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size Estimates and Forecasts

1.4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2020-2031

1.4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2020-2031

1.4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition by Manufacturers

2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Manufacturers (2020-2025)

2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Monoclonal Antibodies for Non-small Cell Lung Cancer, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Product Type & Application

2.7 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Date of Enter into This Industry

2.8 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competitive Situation and Trends

2.8.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Monoclonal Antibodies for Non-small Cell Lung Cancer Players Market Share by Revenue

2.8.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Scenario by Region

3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2020-2031

3.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2020-2025

3.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2026-2031

3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020-2031

3.3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020-2025

3.3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2026-2031

3.4 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country

3.4.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)

3.4.3 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country

3.5.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)

3.5.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Region

3.6.1 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2031)

3.6.3 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country

3.7.1 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)

3.7.3 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country

3.8.1 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)

3.8.3 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2031)

4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2025)

4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2026-2031)

4.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2020-2031)

4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2020-2031)

4.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2020-2025)

4.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2026-2031)

4.2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2020-2031)

4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price by Type (2020-2031)

5 Segment by Application

5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2031)

5.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2025)

5.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2026-2031)

5.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2020-2031)

5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2020-2031)

5.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2020-2025)

5.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2026-2031)

5.2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2020-2031)

5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Roche Holding AG

6.1.1 Roche Holding AG Company Information

6.1.2 Roche Holding AG Description and Business Overview

6.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.1.5 Roche Holding AG Recent Developments/Updates

6.2 Bristol Myers Squibb Co.

6.2.1 Bristol Myers Squibb Co. Company Information

6.2.2 Bristol Myers Squibb Co. Description and Business Overview

6.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.2.5 Bristol Myers Squibb Co. Recent Developments/Updates

6.3 Elea Spa

6.3.1 Elea Spa Company Information

6.3.2 Elea Spa Description and Business Overview

6.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.3.5 Elea Spa Recent Developments/Updates

6.4 Eli Lilly & Co.

6.4.1 Eli Lilly & Co. Company Information

6.4.2 Eli Lilly & Co. Description and Business Overview

6.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.4.5 Eli Lilly & Co. Recent Developments/Updates

6.5 Merck & Co., Inc.

6.5.1 Merck & Co., Inc. Company Information

6.5.2 Merck & Co., Inc. Description and Business Overview

6.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.5.5 Merck & Co., Inc. Recent Developments/Updates

6.6 AstraZeneca PLC

6.6.1 AstraZeneca PLC Company Information

6.6.2 AstraZeneca PLC Description and Business Overview

6.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.6.4 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.6.5 AstraZeneca PLC Recent Developments/Updates

6.7 Regeneron Pharmaceuticals, Inc.

6.7.1 Regeneron Pharmaceuticals, Inc. Company Information

6.7.2 Regeneron Pharmaceuticals, Inc. Description and Business Overview

6.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.7.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates

6.8 Henlius Biopharma Co., Ltd

6.8.1 Henlius Biopharma Co., Ltd Company Information

6.8.2 Henlius Biopharma Co., Ltd Description and Business Overview

6.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.8.5 Henlius Biopharma Co., Ltd Recent Developments/Updates

6.9 Jiangsu Hengrui Medicine Co., Ltd

6.9.1 Jiangsu Hengrui Medicine Co., Ltd Company Information

6.9.2 Jiangsu Hengrui Medicine Co., Ltd Description and Business Overview

6.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.9.5 Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates

6.10 Innovent Biologics Co., Ltd

6.10.1 Innovent Biologics Co., Ltd Company Information

6.10.2 Innovent Biologics Co., Ltd Description and Business Overview

6.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.10.5 Innovent Biologics Co., Ltd Recent Developments/Updates

6.11 Junshi Biosciences Co., Ltd

6.11.1 Junshi Biosciences Co., Ltd Company Information

6.11.2 Junshi Biosciences Co., Ltd Description and Business Overview

6.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.11.5 Junshi Biosciences Co., Ltd Recent Developments/Updates

6.12 BeiGene, Ltd

6.12.1 BeiGene, Ltd Company Information

6.12.2 BeiGene, Ltd Description and Business Overview

6.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.12.4 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.12.5 BeiGene, Ltd Recent Developments/Updates

6.13 Akeso, Inc

6.13.1 Akeso, Inc Company Information

6.13.2 Akeso, Inc Description and Business Overview

6.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio

6.13.5 Akeso, Inc Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Chain Analysis

7.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Production Mode & Process Analysis

7.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales and Marketing

7.4.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Channels

7.4.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors

7.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Customer Analysis

8 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Dynamics

8.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Trends

8.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers

8.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Challenges

8.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Roche Holding AG

Bristol-Myers Squibb Co

Eli Lilly & Co

Merck& Co. Inc

Astrazeneca plc

Regeneron Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Innovent Biologics co Ltd

BeiGene Ltd

Akeso, Inc.

Elea Spa

Henlius Biopharma Co., Ltd

Junshi Biosciences Co., Ltd

List of Tables

Table 1. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competitive Situation by Manufacturers in 2024

Table 4. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Monoclonal Antibodies for Non-small Cell Lung Cancer, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Product Type & Application

Table 12. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibodies for Non-small Cell Lung Cancer as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2025) & (K Units)

Table 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2020-2025)

Table 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2026-2031) & (K Units)

Table 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2026-2031)

Table 21. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2020-2025)

Table 23. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2026-2031)

Table 25. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)

Table 27. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)

Table 28. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)

Table 32. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)

Table 33. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2020-2025)

Table 51. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2026-2031)

Table 52. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2020-2025)

Table 53. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2026-2031)

Table 54. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2020-2025)

Table 57. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2026-2031)

Table 58. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2020-2025)

Table 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2026-2031)

Table 60. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2020-2025)

Table 61. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2026-2031)

Table 62. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2020-2025)

Table 63. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2026-2031)

Table 64. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2020-2025)

Table 67. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2026-2031)

Table 68. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2020-2025)

Table 69. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2026-2031)

Table 70. Roche Holding AG Company Information

Table 71. Roche Holding AG Description and Business Overview

Table 72. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 74. Roche Holding AG Recent Developments/Updates

Table 75. Bristol Myers Squibb Co. Company Information

Table 76. Bristol Myers Squibb Co. Description and Business Overview

Table 77. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 79. Bristol Myers Squibb Co. Recent Developments/Updates

Table 80. Elea Spa Company Information

Table 81. Elea Spa Description and Business Overview

Table 82. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 84. Elea Spa Recent Developments/Updates

Table 85. Eli Lilly & Co. Company Information

Table 86. Eli Lilly & Co. Description and Business Overview

Table 87. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 89. Eli Lilly & Co. Recent Developments/Updates

Table 90. Merck & Co., Inc. Company Information

Table 91. Merck & Co., Inc. Description and Business Overview

Table 92. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 94. Merck & Co., Inc. Recent Developments/Updates

Table 95. AstraZeneca PLC Company Information

Table 96. AstraZeneca PLC Description and Business Overview

Table 97. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 99. AstraZeneca PLC Recent Developments/Updates

Table 100. Regeneron Pharmaceuticals, Inc. Company Information

Table 101. Regeneron Pharmaceuticals, Inc. Description and Business Overview

Table 102. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 104. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates

Table 105. Henlius Biopharma Co., Ltd Company Information

Table 106. Henlius Biopharma Co., Ltd Description and Business Overview

Table 107. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 109. Henlius Biopharma Co., Ltd Recent Developments/Updates

Table 110. Jiangsu Hengrui Medicine Co., Ltd Company Information

Table 111. Jiangsu Hengrui Medicine Co., Ltd Description and Business Overview

Table 112. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 114. Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates

Table 115. Innovent Biologics Co., Ltd Company Information

Table 116. Innovent Biologics Co., Ltd Description and Business Overview

Table 117. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 119. Innovent Biologics Co., Ltd Recent Developments/Updates

Table 120. Junshi Biosciences Co., Ltd Company Information

Table 121. Junshi Biosciences Co., Ltd Description and Business Overview

Table 122. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 124. Junshi Biosciences Co., Ltd Recent Developments/Updates

Table 125. BeiGene, Ltd Company Information

Table 126. BeiGene, Ltd Description and Business Overview

Table 127. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 129. BeiGene, Ltd Recent Developments/Updates

Table 130. Akeso, Inc Company Information

Table 131. Akeso, Inc Description and Business Overview

Table 132. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product

Table 134. Akeso, Inc Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors List

Table 138. Monoclonal Antibodies for Non-small Cell Lung Cancer Customers List

Table 139. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Trends

Table 140. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers

Table 141. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Challenges

Table 142. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

Table 146. Authors List of This Report

List of Figures

Figure 1. Product Picture of Monoclonal Antibodies for Non-small Cell Lung Cancer

Figure 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Type: 2024 & 2031

Figure 4. 5 mg/mL Product Picture

Figure 5. 10 mg/mL Product Picture

Figure 6. 25 mg/mL Product Picture

Figure 7. 50 mg/mL Product Picture

Figure 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Application: 2024 & 2031

Figure 10. Hospitals

Figure 11. Clinic

Figure 12. Others

Figure 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size (2020-2031) & (US$ Million)

Figure 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (2020-2031) & (K Units)

Figure 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit) & (2020-2031)

Figure 17. Monoclonal Antibodies for Non-small Cell Lung Cancer Report Years Considered

Figure 18. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Share by Manufacturers in 2024

Figure 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Monoclonal Antibodies for Non-small Cell Lung Cancer Players: Market Share by Revenue in Monoclonal Antibodies for Non-small Cell Lung Cancer in 2024

Figure 21. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)

Figure 24. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)

Figure 25. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)

Figure 28. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)

Figure 29. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2020-2031)

Figure 36. China Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. China Taiwan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)

Figure 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Colombia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. UAE Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2020-2031)

Figure 55. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2020-2031)

Figure 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2020-2031)

Figure 58. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2020-2031)

Figure 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2020-2031)

Figure 60. Monoclonal Antibodies for Non-small Cell Lung Cancer Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Precision Cancer Imaging System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-23Z10214

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Cryosurgical Equipment for Cancer Treatment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-39B12765

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Brachytherapy Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24Q18678

Tue Feb 18 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Gynecological Cancer Diagnostics Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-30P10282

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions